Edition:
United States

Applied Genetic Technologies Corp (AGTC.OQ)

AGTC.OQ on NASDAQ Stock Exchange Global Market

3.65USD
22 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.65
Open
$3.60
Day's High
$3.65
Day's Low
$3.60
Volume
13,061
Avg. Vol
40,534
52-wk High
$10.70
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Applied Genetic Technologies reports Q4 revenue of $8.3 mln
Wednesday, 13 Sep 2017 07:00am EDT 

Sept 13 (Reuters) - Applied Genetic Technologies Corp ::Q4 revenue $8.3 million versus $12.1 million.Q4 revenue view $11.9 million -- Thomson Reuters I/B/E/S.Q4 ‍loss per share $0.18​.Q4 earnings per share view $0.06 -- Thomson Reuters I/B/E/S.Expected to initiate patient enrollment in XLRP program in Q1 of 2018.Co believes its cash, cash equivalents, investments as of June 30 to be sufficient to fund planned programs for at least the next 2 years.  Full Article

Applied Genetic Technologies partners with the Foundation Fighting Blindness
Tuesday, 15 Aug 2017 07:00am EDT 

Aug 15 (Reuters) - Applied Genetic Technologies Corp ::AGTC and The Foundation Fighting Blindness announce partnership agreement.  Full Article

AGTC files investigational new drug application for treatment of x-linked retinitis pigmentosa
Thursday, 10 Aug 2017 07:00am EDT 

Aug 10 (Reuters) - Applied Genetic Technologies Corp :AGTC files investigational new drug application for the treatment of x-linked retinitis pigmentosa caused by mutations in the RPGR gene.Applied Genetic Technologies-to initiate study evaluating safety & efficacy of gene therapy for XLRP caused by RPGR gene mutations in U.S. in coming months​.  Full Article

AGTC announces FDA orphan drug designation for therapy to treat X-linked retinitis pigmentosa
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Applied Genetic Technologies Corp ::AGTC announces U.S. FDA orphan drug designation for gene therapy to treat X-linked retinitis pigmentosa.  Full Article

AGTC appoints William Sullivan as chief financial officer
Wednesday, 2 Aug 2017 04:01pm EDT 

Aug 2 (Reuters) - Applied Genetic Technologies Corp :AGTC appoints William Sullivan as chief financial officer, Andrew Ashe named general counsel.Applied Genetic Technologies Corp - ‍ Larry Bullock, who has served as chief financial officer, is retiring​.  Full Article

Applied Genetic Technologies updates on clinical development of AGTC-402
Thursday, 15 Jun 2017 07:00am EDT 

June 15 (Reuters) - Applied Genetic Technologies Corp ::Enabling study data published in human gene therapy clinical development support clinical development of AGTC-402 for the treatment of CNGA3-deficient achromatopsia.‍Subretinal injections were generally well tolerated and were not associated with any systemic toxicity​.‍No serum antibodies against human CNGA3 protein were detected in any vector-treated animal​.‍Most animals had mild to moderate side effects thought to be related to surgical procedure.‍Mild to moderate side effects generally resolved without further intervention​.‍Currently scheduling patients for enrollment in Phase I/II trial in patient population.continue enrollment in clinical trial for patients with CNGB3 achromatopsia​.  Full Article

Applied Genetic Technologies quarterly revenue $8.4 million
Wednesday, 10 May 2017 04:08pm EDT 

May 10 (Reuters) - Applied Genetic Technologies Corp :Quarterly revenue $8.4 million versus $12 million.Applied Genetic Technologies -Total revenue for three months ended March 31, 2017 was $8.4 million compared to $12.0 million generated during same period in 2016.Applied Genetic Technologies Corp qtrly loss per share $0.05.Q3 earnings per share view $-0.01, revenue view $10.4 million -- Thomson Reuters I/B/E/S.  Full Article

Applied Genetic Technologies says on April 26 CFO Lawrence Bullock said will retire in near future
Monday, 1 May 2017 07:41am EDT 

May 1 (Reuters) - Applied Genetic Technologies Corp :Applied Genetic Technologies - on April 26 Lawrence Bullock chief financial officer notified his intention to retire in near future.Applied Genetic Technologies Corp- initiated a comprehensive search to identify candidates to succeed Bullock - SEC filing.  Full Article

Applied Genetic Technologies quarterly revenue $10.9 million versus $12.2 million
Wednesday, 8 Feb 2017 04:10pm EST 

Applied Genetic Technologies Corp : Quarterly revenue $10.9 million versus $12.2 million . Applied Genetic Technologies says total revenue for three months ended Dec 31, 2016 was $10.9 million compared to $12.2 million during same period in 2015 .Qtrly earnings per share $ 0.11.  Full Article

Applied Genetic Technologies quarterly EPS $0.20
Tuesday, 8 Nov 2016 04:09pm EST 

Applied Genetic Technologies Corp : Qtrly earnings per share $0.20 .Quarterly revenue $11.8 million versus $11.1 million.  Full Article